ArticlePloS one2026
Physical activity and glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) plasma levels in different age cohorts.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Physical activity (PA) has numerous positive health effects, including improvements in cognitive function. PA stimulates the release of glycosylphosphatidylinositol-specific phospholipase D1 (GPLD1) from the liver, resulting in hippocampal neurogenesis in mice and improved cognition. Interestingly, PA also increases plasma GPLD1 in healthy humans, suggesting a role in cognition, but regulatory factors modulating its concentrations remain unclear. We investigated whether different PA modes, diseases (obesity, hypertension, and diabetes), and age affect plasma GPLD1 levels using three different study cohorts. Plasma GPLD1 levels were analyzed in three studies cohorts comprised of 1) young adults (25 yrs) performing moderate exercise, 2) elderly (68.9 yrs) and 3) of prediabetic subjects (59.4 yrs) performing different habitual PA. We found that prediabetic subjects had higher plasma GPLD1 levels than elderly and young adults. Elderly with diabetes showed significantly higher GPLD1 levels than non-diabetic subjects. In elderly, plasma GPLD1 correlated negatively with average steps, but there was no association after taking their diabetes status into account. GPLD1 exhibited a positive correlation with age in elderly with normal glucose tolerance, and with BMI in subjects with impaired glucose tolerance. Average step numbers negatively correlated with BMI and diastolic BP in the elderly, and BMI in prediabetic subjects. BMI was positively correlated with both diastolic and systolic BP in elderly subjects, and with diastolic BP in young adults. In conclusion age and diabetes affect plasma GPLD1 levels in humans. Age is one of the determining factors, as moderate exercise in young adults did not change plasma GPLD1 levels. Habitual physical activity did not alter plasma GPLD1 levels in individuals with prediabetes or diabetes. The release of GPLD1 into the blood and its mechanistic influences on cognitive functions would need further investigation in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.